Topic 14 — Male Reproductive Disorders: Infertility, Testicular Disease, Prostatic Disorders and Androgen Pharmacology

Connect the major mechanisms, clinical clues, pathology and drug actions into one rapid-revision framework. :contentReference[oaicite:0]{index=0}

1. THE TOPIC IN ONE CONNECTED FLOW

Male reproductive disease becomes easier when the problem is localized first. Dysfunction may involve hormonal stimulation, the testis or sperm pathway, scrotal structures, or the prostate. The same approach then connects mechanism to structural change, clinical presentation, diagnostic clues and treatment.

Site of Problem

Hormonal axis
Testis / sperm pathway
Scrotum
Prostate

→

Core Mechanism

↓ LH/FSH or testicular failure
DHT-driven growth
Venous/fluid abnormality
Neoplastic transformation

→

Functional / Structural Change

Impaired spermatogenesis
Undescended testis
Dilated veins / fluid
Hyperplasia or carcinoma

→

Clinical Presentation

Infertility
Scrotal swelling / mass
Lower urinary symptoms
Bone pain in advanced cancer

→

Diagnostic Clue

Semen + hormones
Scrotal ultrasound
Tumor markers
DRE, PSA, MRI / biopsy

→

Intervention

Gonadotropin replacement
Orchiopexy / scrotal surgery
BPH therapy
Androgen deprivation

→

Outcome / Complication

Infertility
Urinary retention
Renal obstruction
Metastatic disease

Two central hormonal directions:

Infertility from gonadotropin deficiency → give LH-like hCG ± FSH → restore intratesticular testosterone and Sertoli-cell support → improve spermatogenesis.

Androgen-dependent prostatic disease → reduce DHT, androgen synthesis or receptor signaling → reduce androgen-driven tissue stimulation.

2. KEY CLINICAL CONNECTIONS

Infertility: Find the Level of Failure

Low testosterone + low/inappropriately normal LH/FSH → central gonadotropin deficiency → testes lack stimulation → hCG/FSH may restore function.

Low testosterone + high LH/FSH → primary testicular failure → loss of negative feedback → gonadotropins are less useful if testicular tissue has irreversibly failed.

Scrotal Mass: Structure Predicts the Clue

Fluid around testis → hydrocele → cystic swelling that may transilluminate → surgery if persistent and symptomatic.

Dilated pampiniform veins → varicocele → impaired heat exchange → reduced spermatogenesis.

Solid intratesticular lesion → suspect neoplasm → ultrasound + tumor-marker/staging assessment.

Prostate: Site, Mechanism and Treatment Connect

Transition-zone DHT-driven hyperplasia → urethral compression → LUTS → alpha-1 blockade relieves dynamic tone; finasteride reduces DHT-dependent growth.

Peripheral-zone adenocarcinoma → may be silent early → DRE/PSA/MRI/biopsy → advanced androgen-dependent disease is treated by reducing androgen production or receptor signaling.

3. AIM HIGH-YIELD INTEGRATION REVIEW

⭐ Male infertility: semen analysis identifies the sperm abnormality, while LH/FSH/testosterone help localize the defect to central or testicular failure.

Cryptorchidism: abnormal testicular position → higher temperature and germ-cell injury → impaired fertility, with persistent increased tumor risk even after orchiopexy.

Varicocele: venous dilatation → impaired pampiniform heat exchange → adverse testicular environment → reduced spermatogenesis.

⭐ Testicular tumors: morphology + markers guide classification; seminoma is relatively homogeneous, yolk-sac differentiation links with AFP, and choriocarcinoma with β-hCG.

Testicular malignancy: regional retroperitoneal nodal spread indicates more advanced stage than disease confined to the testis; stage, tumor type and marker burden influence prognosis.

⭐ BPH: DHT-dependent periurethral hyperplasia → static obstruction, while alpha-adrenergic smooth-muscle tone adds a dynamic component.

⭐ Prostate carcinoma: peripheral-zone malignant glands → less early urethral obstruction → possible later lymphatic and osteoblastic bone spread; stage and grade determine prognosis.

Androgen pharmacology: testosterone activates intracellular receptors, but exogenous androgen suppresses LH/FSH and may therefore reduce intratesticular testosterone and spermatogenesis.

AIM Exam Trap: BPH and prostate carcinoma can both produce urinary symptoms and an abnormal PSA. BPH is mainly transition-zone hyperplasia causing early obstruction, whereas adenocarcinoma commonly begins in the peripheral zone and may remain asymptomatic until later disease.